- Datum02.05.2024
- Uhrzeit08:00 - 09:00 Uhr
- VeranstalterXTB
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenALX Oncology Holdings Inc. Registered Shares DL-,001 Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Nasdaq | VK | |||||
Nasdaq Basic | VK | |||||
Cboe BZX | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu ALX Oncology Holdings Inc. Registered Shares DL-,001
Webinar zu ALX Oncology Holdings Inc. Registered Shares DL-,001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,936-17,470
- Jahrestief / Hoch ($)10,490-17,470
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von ALX Oncology Holdings Inc. Registered Shares DL-,001
Termine von ALX Oncology Holdings Inc. Registered Shares DL-,001
Beschreibung
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.